Tilray Brands (NASDAQ:TLRY) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Tilray Brands (NASDAQ:TLRY) from a hold rating to a sell rating in a research note published on Saturday.

TLRY has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday, January 21st. Canaccord Genuity Group began coverage on Tilray Brands in a research report on Tuesday, January 27th. They issued a “hold” rating for the company. Zacks Research upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. ATB Cormark Capital Markets raised Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 10th. Finally, Roth Mkm dropped their price objective on shares of Tilray Brands from $20.00 to $10.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Tilray Brands currently has a consensus rating of “Hold” and an average target price of $13.33.

Tilray Brands Stock Performance

Shares of Tilray Brands stock opened at $7.21 on Friday. The company’s 50 day moving average price is $8.29 and its two-hundred day moving average price is $10.95. The firm has a market capitalization of $840.04 million, a P/E ratio of -0.33 and a beta of 1.96. Tilray Brands has a fifty-two week low of $3.51 and a fifty-two week high of $23.20. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.81 and a quick ratio of 1.72.

Tilray Brands (NASDAQ:TLRY) last announced its quarterly earnings results on Thursday, January 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.12. Tilray Brands had a negative net margin of 251.69% and a negative return on equity of 6.35%. The company had revenue of $217.51 million during the quarter, compared to the consensus estimate of $211.15 million. During the same period in the prior year, the business earned ($0.03) earnings per share. On average, equities analysts forecast that Tilray Brands will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Hilton Head Capital Partners LLC acquired a new position in Tilray Brands during the 4th quarter worth about $38,000. Schonfeld Strategic Advisors LLC increased its stake in shares of Tilray Brands by 4.5% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 144,358 shares of the company’s stock valued at $1,304,000 after buying an additional 6,182 shares during the period. IFP Advisors Inc raised its position in shares of Tilray Brands by 14.3% during the fourth quarter. IFP Advisors Inc now owns 60,318 shares of the company’s stock worth $545,000 after acquiring an additional 7,541 shares during the last quarter. Integrated Wealth Concepts LLC raised its position in shares of Tilray Brands by 33.8% during the third quarter. Integrated Wealth Concepts LLC now owns 36,977 shares of the company’s stock worth $64,000 after acquiring an additional 9,341 shares during the last quarter. Finally, CreativeOne Wealth LLC lifted its stake in shares of Tilray Brands by 12.2% in the third quarter. CreativeOne Wealth LLC now owns 87,134 shares of the company’s stock worth $151,000 after acquiring an additional 9,452 shares during the period. 9.35% of the stock is owned by institutional investors.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.